Skip to main content

Blue Owl — Portfolio, Page 3

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

70
Companies
$35.7B
Total invested
$517.6M
Avg. check
35
Industries
Biotechnology 13Health Care 9Medical 6Biopharma 5Pharmaceutical 5Therapeutics 4+29 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 4970 of 70
TORL BioTherapeutics
October 2025

TORL BioTherapeutics is a clinical-stage biopharmaceutical business.

Biopharma · Culver City$96.0M Series C
Star Therapeutics
October 2025

Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.

Health Care · South San Francisco$125.0M Undisclosed
Wrench Group
September 2025

Wrench Group offers home repair, replacement and maintenance services specializing in heating and ventilation.

Electronics · Marietta$1.3B Debt Financing
Celcuity
September 2025

Celcuity is a biotechnology company translating discoveries of new cancer sub-types into expanded therapeutic options for cancer patients.

Biotechnology · Hamel$500.0M Post Ipo Debt
Juniper Square
September 2025

Juniper Square provides software and fund administration services that streamline collaboration and communication between GPs and LPs.

Asset Management · San FranciscoSeries Unknown
MapLight Therapeutics
July 2025

MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.

Biopharma · Palo Alto$372.5M Series D
Madrigal Pharmaceuticals
July 2025

Madrigal Pharmaceuticals is a biopharmaceutical company developing therapeutics for the treatment of cardiovascular-metabolic diseases.

Biopharma · Conshohocken$350.0M Post Ipo Debt
Crusoe AI Data Center
May 2025

Crusoe AI Data Center is a joint venture of Crusoe, Blue Owl Capital and Primary Digital Infrastructure.

Artificial Intelligence (AI) · Denver$11.6B Undisclosed
Latigo Biotherapeutics
March 2025

Latigo Biotherapeutics is a clinical-stage biotechnology company that develops novel, non-opioid therapies for chronic pain.

Biotechnology · Thousand Oaks$150.0M Series B
Perk (formerly TravelPerk)
January 2025

Perk is the intelligent platform for travel and spend.

Artificial Intelligence (AI) · Boston$200.0M Series E
Windward Bio
January 2025

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Biotechnology · Basel$200.0M Series A
Autobahn Therapeutics
July 2024

Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders

Biotechnology · San Diego$100.0M Series C
Cardurion Pharmaceuticals
July 2024

Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.

Biotechnology · Boston$260.0M Series B
Lycia Therapeutics
May 2024

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Biotechnology · South San Francisco$106.6M Series C
Context Therapeutics
May 2024

Context Therapeutics is a clinical-stage biopharmaceutical company.

Biotechnology · Philadelphia$100.0M Post Ipo Equity
Cullinan Therapeutics
April 2024

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Biopharma · Cambridge$280.0M Post Ipo Equity
Alterome Therapeutics
April 2024

Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.

Biopharma · San Diego$132.0M Series B
Obsidian Therapeutics
April 2024

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Biotechnology · Cambridge$160.5M Series C
Finastra
August 2023

Finastra provides the broadest portfolio of financial services software.

Financial Services · Paddington$5.3B Debt Financing
6sense
June 2023

6sense is an account-based marketing platform that helps B2B organizations achieve predictable revenue growth.

Artificial Intelligence (AI) · San Francisco$100.0M Debt Financing
Coherent
April 2022

Coherent is a software-as-a-service company for insurance companies.

Information Technology · New York$75.0M Series B
QuVa Pharma
May 2021

QuVa Pharma is a quality-compliant manufacturer of compounded and ready-to-administer sterile injectable products.

Health Care · Sugar Land$275.0M Debt Financing

Where Blue Owl invests

Biotechnology13
Health Care9
Medical6
Biopharma5
Pharmaceutical5
Therapeutics4

About Blue Owl's portfolio

How many companies has Blue Owl invested in?

Blue Owl has invested in 70 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Blue Owl invest in?

Blue Owl's top investment sectors include Biotechnology, Health Care, Medical, Biopharma, Pharmaceutical. The firm invests across 35 different industry categories.

What is Blue Owl's largest investment?

Among tracked funding rounds, Crusoe AI Data Center received $11.6B in a Undisclosed round. Blue Owl's total known invested capital is $35.7B.

What is the average investment size for Blue Owl?

Blue Owl's average investment size is $517.6M across its portfolio of 70 companies.

What are Blue Owl's most recent investments?

Recent Blue Owl portfolio additions include TORL BioTherapeutics, Star Therapeutics, Wrench Group, Celcuity, Juniper Square. These companies were founded in 2020 or later.

Reach the founders behind these 70 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →